Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.

Tumors may escape immune recognition and destruction through the induction of apoptosis in activated T lymphocytes. Results from several laboratories suggest that FasL (L/CD95L) expression in tumors may be responsible for this process. In this study of patients with renal cell carcinoma (RCC), we provide evidence for two mechanisms of T-cell apoptosis. One mechanism involves the induction of apoptosis via FasL expression in tumor cells. This is supported by several observations, including the fact that tumor cells in situ as well as cultured cell lines expressed FasL mRNA and protein by a variety of techniques. The FasL in RCC is functional because in coculture experiments, FasL+ tumors induced apoptosis in Fas-sensitive Jurkat T cells and in activated peripheral blood T cells but not in resting peripheral blood T cells. Most importantly, antibody to FasL partially blocked apoptosis of the activated T cells. Moreover, Fas was expressed by T cells derived from the peripheral blood (53% median) and tumor (44.3% median) of RCC patients. Finally, in situ staining for DNA breaks demonstrated apoptosis in a subset of T cells infiltrating renal tumors. These studies also identified a second mechanism of apoptosis in RCC patient peripheral T cells. Whereas these cells did not display DNA breaks when freshly isolated or after culture for 24 h in medium, peripheral blood T cells from RCC patients underwent activation-induced cell death after stimulation with either phorbol 12-myristate 13-acetate/ionomycin or anti-CD3/CD28 antibodies. Apoptosis mediated by exposure to FasL in tumor cells or through T-cell activation may contribute to the failure of RCC patients to develop an effective T-cell-mediated antitumor response.

[1]  P. Hainaut,et al.  Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. , 1998, Cancer research.

[2]  P. Krammer,et al.  Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. , 1994, Journal of immunology.

[3]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[4]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[5]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[6]  A. Schned,et al.  Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. , 1998, Cancer research.

[7]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[8]  J. Montie,et al.  Tumor‐Infiltrating Lymphocytes in Patients with Renal‐Cell Carcinoma , 1988, Annals of the New York Academy of Sciences.

[9]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[10]  Frassanito,et al.  CD8+/CD57+ cells and apoptosis suppress T‐cell functions in multiple myeloma , 1998, British journal of haematology.

[11]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[12]  L. Genestier,et al.  Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. , 1998, Blood.

[13]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[14]  J. Allison,et al.  Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. , 1986, Journal of immunology.

[15]  D. Smith,et al.  Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. , 1998, Journal of immunology.

[16]  S. Nagata,et al.  Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.

[17]  T. Olencki,et al.  Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor‐infiltrating lymphocytes , 1995, International journal of cancer.

[18]  M. Nagarkatti,et al.  Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. , 1997, Blood.

[19]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[20]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[21]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Walker,et al.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.

[23]  P. Finn,et al.  Fas modulation of apoptosis during negative selection of thymocytes. , 1996, Immunity.

[24]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[25]  E. Halapi,et al.  Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[27]  E. Klein,et al.  T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. , 1993, Cancer research.

[28]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[29]  G. Cohen,et al.  Dissociation of Phagocyte Recognition of Cells Undergoing Apoptosis from Other Features of the Apoptotic Program* , 1998, The Journal of Biological Chemistry.

[30]  S. Burrows,et al.  T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism , 1991, The Journal of experimental medicine.

[31]  S. Miescher,et al.  Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. , 1988, Cancer research.

[32]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[33]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[34]  D. Baltimore,et al.  An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. , 1996, Science.

[35]  T. Roszman,et al.  Modulation of T-cell function by gliomas. , 1991, Immunology today.

[36]  S. Miescher,et al.  Proliferative and cytolytic potentials of purified human tumor‐infiltrating t lymphocytes. Impaired response to mitogen‐driven stimulation despite T‐cell receptor expression , 1988, International journal of cancer.

[37]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[38]  D. Longo,et al.  Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. , 1992, Journal of immunology.

[39]  L. French,et al.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover , 1996, The Journal of cell biology.

[40]  E. Klein,et al.  Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[41]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[42]  E. Klein,et al.  T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. , 1994, Cancer research.

[43]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[44]  T. Pohl,et al.  Antigen‐Induced Death of Mature T Lymphocytes: Analysis by Flow Cytometry , 1994, Immunological reviews.

[45]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.

[46]  A. Novick,et al.  Alterations in NFκB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma , 1999 .

[47]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[48]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[49]  J. Ritz,et al.  Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. , 1997, Journal of immunology.

[50]  K. Sugimachi,et al.  Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. , 1992, Cancer research.

[51]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[52]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.